QLIF-09. LONGTERM SURVIVAL IN GLIOBLASTOMA PATIENTS AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY

INTRODUCTION: Glioblastoma (GBM) is the most common and malignant primary intracranial tumor and traditionally has a median survival of only 10 to 14 months, with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median surviva...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Rulseh, Aaron, Sroubek, Jan, Klener, Jan, Vymazal, Josef
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692852/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.819
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki